Physician profile
Danielle Jessee
NPI 1447894829
$555.42
in general payments reported to CMS, 2019-2025
11 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $68.69 · 2023: $174 · 2024: $86.60 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $143.31 | 2023-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $112.24 | 2021 | |
| Novo Nordisk INC | $101.34 | 2022-2025 | Wegovy |
| Abbvie INC. | $54.35 | 2023-2024 | |
| Glaxosmithkline, LLC. | $31.46 | 2023 | Rotarix, Pediarix, Bexsero |
| Sanofi Pasteur INC. | $27.75 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.95 | 2023 | Keveyis |
| Amgen INC. | $18.94 | 2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $18.30 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $14.29 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Jessee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.